Eyepoint Pharmaceuticals, Inc. $EYPT is Patient Square Capital LP’s 3rd Largest Position

Patient Square Capital LP lowered its stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 25.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,011,839 shares of the company’s stock after selling 340,998 shares during the period. Eyepoint Pharmaceuticals comprises about 3.9% of Patient Square Capital LP’s investment portfolio, making the stock its 3rd biggest holding. Patient Square Capital LP’s holdings in Eyepoint Pharmaceuticals were worth $14,409,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Adage Capital Partners GP L.L.C. raised its holdings in shares of Eyepoint Pharmaceuticals by 9.7% during the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock worth $63,988,000 after acquiring an additional 600,000 shares in the last quarter. Federated Hermes Inc. increased its position in Eyepoint Pharmaceuticals by 12.6% in the 2nd quarter. Federated Hermes Inc. now owns 4,599,450 shares of the company’s stock worth $43,281,000 after purchasing an additional 513,870 shares during the last quarter. Franklin Resources Inc. increased its position in Eyepoint Pharmaceuticals by 3.6% in the 2nd quarter. Franklin Resources Inc. now owns 4,301,123 shares of the company’s stock worth $40,474,000 after purchasing an additional 151,262 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Eyepoint Pharmaceuticals by 8.5% during the 2nd quarter. Bank of America Corp DE now owns 814,153 shares of the company’s stock worth $7,661,000 after purchasing an additional 63,941 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in shares of Eyepoint Pharmaceuticals by 0.9% during the 2nd quarter. Hsbc Holdings PLC now owns 631,074 shares of the company’s stock valued at $5,945,000 after buying an additional 5,934 shares during the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT opened at $15.33 on Monday. The company has a market capitalization of $1.27 billion, a PE ratio of -5.13 and a beta of 1.76. Eyepoint Pharmaceuticals, Inc. has a one year low of $3.91 and a one year high of $19.11. The company’s fifty day moving average price is $15.72 and its 200 day moving average price is $13.93.

Analyst Upgrades and Downgrades

Several brokerages recently commented on EYPT. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Thursday, January 22nd. Royal Bank Of Canada boosted their target price on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Cantor Fitzgerald upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, November 25th. Finally, TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $29.25.

Insider Buying and Selling at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $17.10, for a total transaction of $727,502.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.46% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.